Akcea Therapeutics (AKCA) Tops Q1 EPS by 4c

Akcea Therapeutics (NASDAQ: AKCA) reported Q1 EPS of ($0.42), $0.04 better than the analyst estimate of ($0.46). Revenue for the quarter came in at $16.1 million versus the consensus estimate of $34.85 million.

"This has been an exciting quarter with significant progress made across the company," said Damien McDevitt, chief executive officer of Akcea. \"With the two positive data readouts for AKCEA-ANGPTL3-LRx, which we are now referring to as vupanorsen, and AKCEA-APOCIII-LRx, and additions to our leadership team and board of directors, we have a solid foundation for the future. We are focused on the development and commercialization of medicines for serious and rare diseases, and are committed to bringing products to the rare disease patient community by utilizing a range of solutions to ensure the broadest reach. We generated $15 million in product sales from TEGSEDI and WAYLIVRA in the first quarter, as we continue to expand the number of countries where our products are commercially available, and ended the quarter with $421 million in cash, cash equivalents and short-term investments, putting us in a very strong position to execute on our strategic priorities in 2020 and beyond."

For earnings history and earnings-related data on Akcea Therapeutics (AKCA) click here.

You May Also Be Interested In

• Are we witnessing a fundamental or speculative rally in the S&P 500?
• Fairfax prices $750 million senior notes offering at 6.200% interest
• IDT Corp. (IDT) Tops Q3 EPS by 2c; offer guidance